Financial Daily from THE HINDU group of publications
Friday, Oct 22, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate Results - Pharmaceuticals


Nicholas Piramal Q2 net up at Rs 54.39 crore; stock split okayed

Our Bureau

Mumbai , Oct. 21

DRUG company Nicholas Piramal India Ltd (NPIL) has posted a net profit of Rs 54.39 crore for the quarter ended September 30, as against Rs 50.52 crore for the same quarter in the previous year.

Total income (net of excise and sales tax) has increased to Rs 360.92 crore (Rs 356. 97 crore).

Further, the company informed the BSE that the group has posted a net profit of Rs 55.77 crore for the quarter ended September 30, as against Rs 52.13 crore last year. Total income (net of excise and sales tax) has increased Rs 382.12 crore (Rs 382.12 crore).

The board of Nicholas Piramal, at its meeting here on Thursday, also approved a 5:1 split of the company's shares. The company's shares will therefore, have a face value of Rs 2 , a company communiqué said.

More Stories on : Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Hikal net profit up 26 per cent


FCI OEN profit rises 66 pc
SPIC posts higher operating loss in H1
Indian Hotels net rises to Rs 22.31 cr
Castrol Q3 net up 8.7%
Nicholas Piramal Q2 net up at Rs 54.39 crore; stock split okayed
Orchid Chem PAT down 42 pc
Divi's Labs Q2 profit falls
Indsil Electro Q1 sales up 42%
Essar Shipping Q2 net surges 46 pc
Alok Ind net up
HCC net at Rs 2.79 cr
Tata Coffee Q2 net climbs 35 pc
HDFC Bank Q2 net up 30 pc — Board approves $300-m ADS plan
Treasury gains dented; ICICI Bank Q2 net rises 10 pc
Corpn Bank Q2 net down 81 pc



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line